Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Bavarian Nordic A/S Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents August 16, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine August 13, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production August 08, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA June 26, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate June 17, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine May 31, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate April 29, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. April 02, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency February 23, 2024 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents August 06, 2023 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government August 03, 2023 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate June 27, 2023 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age June 20, 2023 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions February 15, 2023 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine December 23, 2022 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults December 22, 2022 From Bavarian Nordic A/S Via GlobeNewswire Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial October 17, 2022 From Bavarian Nordic A/S Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.